3-chloro-1H-isoindol-1-one | 23661-69-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 3-chloro-1H-isoindol-1-one
• 英文别名: 3-chloro-isoindol-1-one；3-Chlor-isoindol-1-on；3-Chloroisoindol-1-one
• CAS: 23661-69-0
• 化学式: C₈H₄ClNO
• 分子量: 165.579
• InChiKey: BFYDTPYCUVVKGG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  29.4
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-chloro-1H-isoindol-1-one 、 N-(3-methylphenyl)-4-aminobenzamide 以 1,4-二氧六环 为溶剂， 反应 3.0h， 以60.1%的产率得到4-[(1-oxo-1H-isoindol-3-yl)amino]-N-(m-tolyl)benzamide
  参考文献：
  名称：

  Virtual Screening and Synthesis of New Chemical Scaffolds as VEGFR-2 Kinase Inhibitors

  摘要：

  Background: VEGFR-2 tyrosine kinase inhibitors are currently receiving high interest in drug discovery process as anticancer agents. We have used virtual screening techniques in order to discover new scaffolds that can be used for developing new VEGFR-2 kinase inhibitors.Method: Similarity ensemble approach was used to reduce the chemical space of ZINC database to select a subset of compounds. A validated structure-based pharmacophore was developed and adopted to screen the selected subset. Initial hits mapped to the pharmacophore were filtered using docking and scoring. Selected compounds were synthesized and biologically tested.Results: Compound 9 showed very good cytotoxicity profile against the NCI 60 cancer cell lines, while compound 8 showed reasonable inhibition of VEGFR-2 tyrosine kinase.Conclusion: Stepwise virtual screening of databases such as ZINC may result in new scaffolds for developing VEGFR-2 kinase inhibitors.

  DOI：

  10.1055/s-0032-1323759
• 作为产物：
  描述：

  N-(Chlorformyl)-phthalimid 以84%的产率得到
  参考文献：
  名称：

  SHELUDYAKOV V. D.; TKACHEV A. S.; SHELUDYAKOVA S. V.; MIRONOV V. F., ZH. OBSHCH. XIMII, 1977, 47 HO 5, 1063-1068

  摘要：

  DOI：

文献信息

• [EN] ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS<br/>[FR] COMPOSES A BASE D'ISOINDOLONE ET LEUR UTILISATION COMME POTENTIALISATEURS DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
  申请人：ASTRAZENECA AB

  公开号：WO2006020879A1

  公开（公告）日：2006-02-23

  The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.

  本发明涉及式(I)的化合物，其中R1是一个环，n是1到8之间的数字。该发明还涉及将这些化合物用于治疗作为代谢型谷氨酸受体调节剂，特别是在神经系统和精神疾病中的用途。
• Benzo-fused heterocyclic compounds
  申请人：AMERICAN HOME PRODUCTS CORPORATION

  公开号：EP0081955A2

  公开（公告）日：1983-06-22

  The invention concerns compounds of the formula: wherein R is mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, cycloalkyl of 5-7 carbon atoms, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkanoylamino, lower alkyl thio, lower alkylsulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, amino, cyano or nitro. and A is amine selected from wherein R1 is hydrogen or R2CH2 wherein R2 is mono- or diloweralkylamino, mono- or di-N-lower alkylaminoloweral- kyl, (2-furyl)methylamino, benzylamino, lowercycloalkylamino, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl, 4-morpholinyl or 4-thiomorpholinyl; R3 is hydrogen or (1-piperidinyl)methyl with the proviso that when R3 is (1-piperidinyl)methyl, R1 is hydrogen; n is 1 to 4 and the pharmacologically acceptable salts thereof; which inhibit gastric acid secretion. Processes for preparing the compounds and pharmaceutical compositions containing them are also disclosed.

  本发明涉及式中的化合物： 其中 R 是单卤或二卤、氨基、硝基、氰基、羟基、三氟甲基、巯基、低级烷基、低级烷氧基、烷酰基、5-7 个碳原子的环烷基、羧基、烷氧基羰基、单或双低级烷基取代的氨基、烷酰氨基、低级烷基硫代、低级烷基磺酰基、氨基磺酰基、低级烷基取代的氨基磺酰基、苯基或苯基取代的苯基、烷酰氨基、低级烷基硫代、低级烷基磺酰基、氨基磺酰基、低级烷基取代的氨基磺酰基、苯基或被卤素、低级烷基、低级烷氧基、三氟甲基、羟基、氨基、氰基或硝基取代的苯基。 和 A 是胺，选自 其中 R1 是氢或 R2CH2 其中 R2 是单-或稀低烷基氨基、单-或二-N-低烷基氨基低醛基、(2-呋喃基)甲基氨基、苄基氨基、低环烷基氨基、1-吡咯烷基、1-哌啶基、1-六氢氮杂卓基、1-八氢氮杂卓基、3-噻唑烷基、4-吗啉基或 4-硫代吗啉基；R3是氢或(1-哌啶基)甲基，但当R3是(1-哌啶基)甲基时，R1是氢；n是1至4及其药理上可接受的盐；这些化合物可抑制胃酸分泌。此外，还公开了制备这些化合物和含有这些化合物的药物组合物的工艺。
• Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
  申请人：AstraZeneca AB

  公开号：EP2357169A1

  公开（公告）日：2011-08-17

  The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  本发明涉及式 I 的化合物： 其中 R1、R2、R3、R4、R5、R6、R7、R8、R9 和 n 如描述中对式 I 所定义。本发明还涉及这些化合物的制备工艺、制备过程中使用的新中间体、含有这些化合物的药物组合物以及这些化合物在治疗中的应用。
• Synthesis of Hetaryl Glycosides and Their Glycosyl Donor Properties
  作者：Ursula Huchel、Christoph Schmidt、Richard R. Schmidt

  DOI：10.1002/(sici)1099-0690(199807)1998:7<1353::aid-ejoc1353>3.0.co;2-c

  日期：1998.7
• US2701252
  申请人：——

  公开号：——

  公开（公告）日：——